HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Kim, Young Rang ^a   Oh, Kyung Jin ^a   Park, Ra Young ^a   Xuan, Nguyen T ^a   Kang, Taek Won ^a,b   Kwon, Dong Deuk ^a,b   Choi, Chan ^a,b   Kim, Min S ^b   Nam, Kwang I ^a,b   Ahn, Kyu Y ^a,b   Jung, Chaeyong ^a,b  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1; HOMEODOMAIN PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN HOXB13; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HOXB13 PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL SURVIVAL; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION; AGED; ANTIBODY SPECIFICITY; GENETIC TRANSFECTION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; E2F TRANSCRIPTION FACTORS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 77952716929     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-124     Document Type: Article

References (47)

1. Podlasek CA, Clemens JQ, Bushman W. Hoxa-13 gene mutation results in abnormal seminal vesicle and prostate development. J Urol 1999, 161:1655-1661. 10.1016/S0022-5347(05)68999-9, 10210434.
2. Podlasek CA, Duboule D, Bushman W. Male accessory sex organ morphogenesis is altered by loss of function of Hoxd-13. Dev Dyn 1997, 208:454-465. 10.1002/(SICI)1097-0177(199704)208:4<454::AID-AJA2>3.0.CO;2-H, 9097018.
3. Podlasek CA, Seo RM, Clemens JQ, Ma L, Maas RL, Bushman W. Hoxa-10 deficient male mice exhibit abnormal development of the accessory sex organs. Dev Dyn 1999, 214:1-12. 10.1002/(SICI)1097-0177(199901)214:1<1::AID-DVDY1>3.0.CO;2-2, 9915571.
4. Zeltser L, Desplan C, Heintz N. Hoxb-13: a new Hox gene in a distant region of the HOXB cluster maintains colinearity. Development 1996, 122:2475-2484.
5. Sreenath T, Orosz A, Fujita K, Bieberich CJ. Androgen-independent expression of hoxb-13 in the mouse prostate. Prostate 1999, 41:203-207. 10.1002/(SICI)1097-0045(19991101)41:3<203::AID-PROS8>3.0.CO;2-J, 10517879.
6. Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science 2004, 306:640-643. 10.1126/science.1104635, 15499008.
7. Economides KD, Zeltser L, Capecchi MR. Hoxb13 mutations cause overgrowth of caudal spinal cordand tail vertebrae. Dev Biol 2003, 256:317-33. 10.1016/S0012-1606(02)00137-9, 12679105.
8. Economides KD, Capecchi MR. Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development 2003, 130:2061-2069. 10.1242/dev.00432, 12668621.
9. Golias C, Iliadis I, Peschos D, Charalabopoulos K. Amplification and co-regulators of androgen receptor gene in prostate cancer. Exp Oncol 2009, 31:3-8.
10. Nieto M, Finn S, Loda M, Hahn WC. Prostate cancer: Re-focusing on androgen receptor signaling. Int J Biochem Cell Biol 2007, 39:1562-1568. 10.1016/j.biocel.2007.01.005, 2000831, 17321194.
11. Kokontis J, Takakura K, Hay N, Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994, 54:1566-1573.
12. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001, 61:3550-3555.
13. Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, Fletcher A, Edwards S, Flohr P, Falconer A, et al. Amplification and overexpression of E2F3 in human bladder cancer. Exp Cell Res 2004, 293:144-153. 10.1016/j.yexcr.2003.09.024, 14729064.
14. Takahashi Y, Hamada J, Murakawa K, Takada M, Tada M, Nogami I, Hayashi N, Nakamori S, Monden M, Miyamoto M, et al. Expression profiles of 39 HOX genes in normal human adult organs and anaplastic thyroid cancer cell lines by quantitative real-time RT-PCR system. Exp Cell Res 2004, 293:144-153. 10.1016/j.yexcr.2003.09.024, 14729064.
15. Jung C, Kim RS, Zhang HJ, Lee SJ, Jeng MH. HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res 2004, 64:9185-9192. 10.1158/0008-5472.CAN-04-1330, 15604291.
16. Edwards S, Campbell C, Flohr P, Shipley J, Giddings I, Te-Poele R, Dodson Y, Foster C, Clark J, Jhavar S, et al. Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer. Br J Cancer 2005, 92:376-381. 10.1038/sj.bjc.6602261, 2361840, 15583692.
17. Jung C, Kim RS, Lee SJ, Wang C, Jeng MH. HOXB13 Homeodomain Protein Suppresses the Growth of Prostate Cancer Cells by the Negative Regulation of T-Cell Factor 4. Cancer Res 2004, 64:3046-3051. 10.1158/0008-5472.CAN-03-2614, 15126340.
18. Bracken AP, Ciro M, Cocito A, Helin K. E2F target genes: unraveling the biology. Trends Biochem Sci 2004, 29:409-417. 10.1016/j.tibs.2004.06.006, 15362224.
19. Hurford RK, Cobrinik D, Lee MH, Dyson N. pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes Dev 1997, 11:1447-1463. 10.1101/gad.11.11.1447, 9192872.
20. Libertini SJ, Tepper CG, Guadalupe M, Lu Y, Asmuth DM, Mudryj M. E2F1 expression in LNCaP prostate cancer cells deregulates androgen dependent growth, suppresses differentiation, and enhances apoptosis. Prostate 2006, 66:70-81. 10.1002/pros.20314, 16114066.
21. Rodriguez BA, Cheng AS, Yan PS, Potter D, Agosto-Perez FJ, Shapiro CL, Huang TH. Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer. Carcinogenesis 2008, 29:1459-1465. 10.1093/carcin/bgn115, 18499701.
22. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E, Trombetta ES, et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004, 64:5270-5282. 10.1158/0008-5472.CAN-04-0731, 15289333.
23. Jung C, Kim RS, Zhang H, Lee SJ, Sheng H, Loehrer PJ, Gardner TA, Jeng MH, Kao C. HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation. Br J Cancer 2005, 92:2233-2239. 10.1038/sj.bjc.6602631, 2361828, 15928669.
24. Komuves LG, Ma XK, Stelnicki E, Rozenfeld S, Oda Y, Largman C. HOXB13 homeodomain protein is cytoplasmic throughout fetal skin development. Dev Dyn 2003, 227:192-202. 10.1002/dvdy.10290, 12761847.
25. Zhao Y, Yamashita T, Ishikawa M. Regulation of tumor invasion by HOXB13 gene overexpressed in human endometrial cancer. Oncol Rep 2005, 13:721-726.
26. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004, 5:607-616. 10.1016/j.ccr.2004.05.015, 15193263.
27. Reid JF, Lusa L, De Cecco L, Coradini D, Veneroni S, Daidone MG, Gariboldi M, Pierotti MA. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst 2005, 97:927-930.
28. Miao J, Wang Z, Provencher H, Muir B, Dahiya S, Carney E, Leong CO, Sgroi DC, Orsulic S. HOXB13 promotes ovarian cancer progression. Proc Natl Acad Sci USA 2007, 104:17093-17098. 10.1073/pnas.0707938104, 2040435, 17942676.
29. Okuda H, Toyota M, Ishida W, Furihata M, Tsuchiya M, Kamada M, Tokino T, Shuin T. Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma. Oncogene 2006, 25:1733-1742. 10.1038/sj.onc.1209200, 16278676.
30. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, Gasser TC, Koivisto P, Lack EE, Kononen J, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000, 60:6111-6115.
31. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002, 1:203-209. 10.1016/S1535-6108(02)00030-2, 12086878.
32. Waltregny D, Alami Y, Clausse N, de Leval J, Castronovo V. Overexpression of the homeobox gene HOXC8 in human prostate cancer correlates with loss of tumor differentiation. Prostate 2002, 50:162-169. 10.1002/pros.10045, 11813208.
33. Johnson PH, Walker RP, Jones SW, Stephens K, Meurer J, Zajchowski DA, Luke MM, Eeckman F, Tan Y, Wong L, et al. Multiplex gene expression analysis for high-throughput drug discovery: screening and analysis of compounds affecting genes overexpressed in cancer cells. Mol Cancer Ther 2002, 1:1293-1304.
34. Fromont G, Chene L, Latil A, Bieche I, Vidaud M, Vallancien G, Mangin P, Fournier G, Validire P, Cussenot O. Molecular profiling of benign prostatic hyperplasia using a large scale real-time reverse transcriptase-polymerase chain reaction approach. J Urol 2004, 172:1382-1385. 10.1097/01.ju.0000137819.92305.46, 15371850.
35. Birkenkamp-Demtroder K, Olesen SH, Sorensen FB, Laurberg S, Laiho P, Aaltonen LA, Orntoft TF. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 2005, 54:374-384. 10.1136/gut.2003.036848, 1774427, 15710986.
36. Clark J, Edwards S, John M, Flohr P, Gordon T, Maillard K, Giddings I, Brown C, Bagherzadeh A, Campbell C, et al. Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones. Genes Chromosomes Cancer 2002, 34:104-114. 10.1002/gcc.10039, 11921288.
37. McMullin RP, Mutton LN, Bieberich CJ. Hoxb13 regulatory elements mediate transgene expression during prostate organogenesis and carcinogenesis. Dev Dyn 2009, 238:664-672. 10.1002/dvdy.21870, 19191217.
38. Adams PD, Kaelin WG. The cellular effects of E2F overexpression. Curr Top Microbiol Immunol 1996, 208:79-93.
39. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993, 365:349-352. 10.1038/365349a0, 8377827.
40. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
41. Sherr CJ. Cancer cell cycles. Science 1996, 274:1672-1677. 10.1126/science.274.5293.1672, 8939849.
42. Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, Southgate C, Dowe A, Dearnaley D, Jhavar S, et al. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 2004, 23:5871-5879. 10.1038/sj.onc.1207800, 15184867.
43. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412:822-826. 10.1038/35090585, 11518967.
44. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003, 95:661-668.
45. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. Jama 2002, 287:1662-1670. 10.1001/jama.287.13.1662, 11926890.
46. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995, 55:5187-5190.
47. Jung C, Ou YC, Yeung F, Frierson HF, Kao C. Osteocalcin is incompletely spliced in non-osseous tissues. Gene 2001, 271:143-150. 10.1016/S0378-1119(01)00513-3, 11418235.